natgillin/translations-raw huggingface dataset:
Section 4.8 - Undesirable effects: Respiratory, thoracic and mediastinal disorders 
Poglavje 4.8 - Neželeni učinki: Bolezni dihal, prsnega koša in mediastinalnega prostora
Pulmonary symptoms, such as cough and dyspnoea, may be a reason for discontinuation of the therapy and for further investigation, as appropriate. 
Pljučni simptomi, npr. kašelj in dispneja, so lahko razlog za prekinitev zdravljenja in nadaljnjo preiskavo, če je to potrebno.
- a cough or breathing problems as these may indicate inflammation problems of the lung (interstitial lung disease or pulmonary hypertension); 
- kašelj ali oteženo dihanje, ki lahko nakazujeta težave s pljuči vnetje pljuč (intersticijska bolezen pljuč ali pljučna hipertenzija);
Section 4.8 Very rare: Osteonecrosis of the external auditory canal (bisphosphonate class adverse reaction). 
Poglavje 4.8 Zelo redki: Osteonekroza zunanjega slušnega kanala (neželeni učinek skupine bisfosfonatov).
HLA-DRB1*04:03 allele (susceptibility to IAS odds ratio: 1.6) is especially found in Caucasians, with a higher prevalence in southern than in northern Europe and HLA-DRB1*04:06 allele (susceptibility to IAS odds ratio: 56.6) is especially found in Japanese and Korean patients. 
Alel HLA-DRB1*04:03 (razmerje obetov za dovzetnost za IAS: 1,6) je prisoten zlasti pri belcih, z večjo razširjenostjo v južni Evropi kot v severni, alel HLA-DRB1*04:06 (razmerje obetov za dovzetnost za IAS: 56,6) pa je zlasti prisoten pri japonskih in korejskih bolnikih.
The risk of its their occurrence is can be increased in patients with a history of interstitial lung disease. 
Tveganje za njen njun pojav je lahko povečano pri bolnikih z anamnezo intersticijske bolezni pljuč.
IAS should be considered in the differential diagnosis of spontaneous hypoglycaemia in patients using thioctic acid (see section 4.8). 
IAS je treba upoštevati pri diferencialni diagnozi spontane hipoglikemije pri bolnikih, ki uporabljajo tioktično kislino (glejte poglavje 4.8).
Leflunomide - Pulmonary hypertension (EPITT no 18221) 
Leflunomid1 - Pljučna hipertenzija (EPITT št. 18221)
• Talk to your doctor if you have ear pain, discharge from the ear, and/or an ear infection. 
• V primeru bolečine v ušesu, izcedka iz ušesa in/ali okužbe ušesa se posvetujte s svojim zdravnikom.
Patients with a certain human leukocyte antigen genotype (which is more frequent in Japanese and Korean patients, but is also found in Caucasians) are more prone to development of insulin autoimmune syndrome (disorder of the blood glucose regulating hormones with pronounced lowering of blood sugar levels) when treated with thioctic acid. 
Bolniki z določenim genotipom humanega levkocitnega antigena (ki je pogostejši pri japonskih in korejskih bolnikih, vendar je prisoten tudi pri belcih) so bolj dovzetni za nastanek insulinskega avtoimunega sindroma (motnja hormonov za uravnavanje glukoze v krvi z izrazitim znižanjem koncentracije sladkorja v krvi) med zdravljenjem s tioktično kislino.
Frequency unknown: insulin autoimmune syndrome (see section 4.4) 
Neznana pogostnost: insulinski avtoimuni sindrom (glejte poglavje 4.4)
Patients with human leukocyte antigen genotype such as HLA-DRB1*04:06 and HLA-DRB1*04:03 alleles, are more susceptible to develop IAS when treated with thioctic acid. 
Bolniki z genotipom humanega levkocitnega antigena, kot sta alela HLA-DRB1*04:06 in HLA-DRB1*04:03, so bolj dovzetni za nastanek IAS med zdravljenjem s tioktično kislino.
Frequency unknown: Disorder of the blood glucose regulating hormones with pronounced lowering of blood sugar levels (insulin autoimmune syndrome). 
Neznana pogostnost: Motnja hormonov za uravnavanje glukoze v krvi z izrazitim znižanjem koncentracije sladkorja v krvi (insulinski avtoimuni sindrom).
Interstitial lung disease, as well as rare cases of pulmonary hypertension has have been reported during treatment with leflunomide (see section 4.8). 
Med zdravljenjem z leflunomidom je bila opisana intersticijska bolezen pljuč, pa tudi redki primeri pljučne hipertenzije (glejte poglavje 4.8).
Trabectedin - Capillary leak syndrome (EPITT no 18115) 
Trabektedin - sindrom povečane prepustnosti kapilar (EPITT št. 18115)
Cases of Insulin Autoimmune Syndrome (IAS) have been reported during treatment with thioctic acid. 
Med zdravljenjem s tioktično kislino so poročali o primerih insulinskega avtoimunega sindroma (IAS).
Frequency ‘uncommon': Cases of suspected capillary leak syndrome have been reported with trabectedin. 
Pogostnost „občasna“: Pri uporabi trabektedina so poročali o primerih domnevnega sindroma povečane prepustnosti kapilar.
Other side effects such as kidney failure, a decrease in the levels of uric acid in your blood, pulmonary hypertension, male infertility [...] may also occur with an unknown frequency. 
Pojavijo se lahko tudi drugi neželeni učinki, katerih pogostnost ni znana, kot so ledvična odpoved, zmanjšana koncentracija sečne kisline v krvi, pljučna hipertenzija, neplodnost pri moških [...].
Thioctic acid - Insulin autoimmune syndrome (EPITT no 
Tioktinska kislina - insulinski avtoimuni sindrom (EPITT št. 18406)
The way it works in this disease is not completely understood. 
Način delovanja pri tej bolezni ni v celoti znan.
As the company had supplied the additional information requested, the ‘exceptional circumstances' ended on 10 August 2010. 
Ker je družba predložila zahtevane dodatne informacije, so „izjemne okoliščine“ prenehale veljati 10. avgusta 2010.
If this does not happen by day 50 (for previously treated patients) or by day 60 (for newly diagnosed patients), the treatment should be stopped. 
Če se to ne zgodi do 50. dneva (pri predhodno zdravljenih bolnikih) ali do 60. dneva (pri novo diagnosticiranih bolnikih), je treba zdravljenje prekiniti.
Forty-five of the patients in the studies were adults. 
45 bolnikov v študiji je bilo odraslih.
The treatment is divided into 2 phases: induction and consolidation. 
Zdravljenje je razdeljeno na dve stopnji: uvodno in utrditveno.
On average, it took 57 days for the patients to reach complete remission. 
Povprečno je bilo potrebnih 57 dni, da je bolnik dosegel popolno remisijo.
The main measure of effectiveness was the number of patients who had complete remission. 
Glavno merilo učinkovitosti je bil število bolnikov, pri katerih je bila dosežena popolna remisija.
The European Commission granted a marketing authorisation valid throughout the European Union for Trisenox on 5 March 2002. 
Evropska komisija je dovoljenje za promet z zdravilom Trisenox, veljavno po vsej Evropski uniji, izdala 5. marca 2002.
This is a summary of the European public assessment report (EPAR) for Trisenox. 
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Trisenox.
It is thought to prevent the production of DNA, which is necessary for leukaemia cells to grow. 
Predvideva se, da preprečuje proizvodnjo DNK, ki je potrebna za rast levkemičnih celic.
The full EPAR for Trisenox can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports. 
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Trisenox je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The infusion should last one to two hours, but it may last longer if the patient has certain side effects. 
Infundiranje mora trajati od ene do dveh ur, lahko pa tudi dlje, če se pri bolniku pojavijo določeni neželeni učinki.
What measures are being taken to ensure the safe and effective use of Trisenox? 
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Trisenox?
The CHMP decided that Trisenox's benefits are greater than its risks and recommended that it be given marketing authorisation. 
Odbor CHMP je zaključil, da so koristi zdravila Trisenox večje od z njim povezanih tveganj, in priporočil, da se zanj izda dovoljenje za promet.
Looking at the results of these two studies together, 87% of the patients had complete remission (45 out of 52). 
Pri pregledu rezultatov obeh študij skupaj je popolno remisijo doseglo 87 % (45 od 52)bolnikov.
• Patients with APL whose disease has not responded to previous treatment with a retinoid and cancer medicines, or when their disease has come back after this type of treatment. 
• bolnikih, katerih bolezen se ni odzvala na predhodno zdravljenje z retinoidi in zdravili za zdravljenje raka ali kadar se je bolezen po taki vrsti zdravljenja ponovila.
The most common side effects with Trisenox (seen in 1 patient in 10) are hyperglycaemia (high blood glucose levels), hypomagnesaemia (low blood magnesium levels), hypokalaemia (low blood potassium levels), paraesthesia (unusual sensations like pins and needles), dizziness, headache, tachycardia (rapid heartbeat), dyspnoea (difficulty breathing), differentiation syndrome (a potentially fatal complication of chemotherapy in patients with APL), diarrhoea, vomiting, nausea (feeling sick), pruritus (itching), rash, myalgia (muscle pain), pyrexia (fever), pain, fatigue (tiredness), oedema (swelling), prolonged QT interval on an electrocardiogram (an alteration of the electrical activity of the heart), and increased levels of alanine aminotransferase and aspartate aminotransferase (liver enzymes). 
Najpogostejši neželeni učinki zdravila Trisenox (opaženi pri 1 bolniku od 10) so hiperglikemija (povečane ravni glukoze v krvi), hipomagneziemija (nizke ravni magnezija v krvi), hipokaliemija (nizke ravni kalija v krvi), parestezija (nenavadni občutki zbadanja), omotica, glavobol, tahikardija (hitro bitje srca), dispneja (oteženo dihanje), sindrom diferenciacije (morebitni usodni zapleti pri kemoterapiji pri bolnikih z akutno promielocitno levkemijo), driska, bruhanje, navzeja (slabost), pruritus (srbenje), izpuščaj, mialgija (bolečine v mišicah), pireksija (povišana telesna temperatura), bolečine, utrujenost, edem (otekanje), podaljšan interval QT na elektrokardiogramu (sprememba električne dejavnosti srca) ter povišane ravni alanin aminotrasferaze in aspartat aminotransferaze (jetrnih encimov).
97% (72 out of 74) of patients treated with Trisenox did not have any event, compared with 86% (65 out of 76) of those treated with anthracyclines. 
Pri 97 % (72 od 74) bolnikov, ki so bili zdravljeni z zdravilom Trisenox, se ni pojavil noben dogodek primerjavi s 86 % (65 od 76) bolnikov, ki so bili zdravljeni s antraciklini.
This is when there are no more leukaemia cells in the bone marrow and the levels of platelets and white blood cells in the blood have recovered. 
To pomeni, da v kostnem mozgu ni bilo več levkemičnih celic, ravni trombocitov in belih krvnih celic v krvi pa so se popravile.
Trisenox was originally authorised under ‘exceptional circumstances', because, as the disease is rare, limited information was available at the time of approval. 
Zdravilo Trisenox je pridobilo dovoljenje za promet v „izjemnih okoliščinah“, saj so bile zaradi redkosti bolezni ob odobritvi zdravila na voljo le omejene informacije.
During the induction phase, Trisenox is given every day until there are signs that the treatment is working (when the bone marrow does not contain any leukaemia cells). 
Med uvodno stopnjo se zdravilo daje vsak dan, dokler se ne pojavijo znaki, da zdravljenje deluje (kostni mozeg ne vsebuje več levkemičnih celic).
The active substance in Trisenox, arsenic trioxide, is a chemical that has been used in medicines for many years, including for the treatment of leukaemia. 
Zdravilna učinkovina v zdravilu Trisenox, arzenov trioksid, je kemikalija, ki se v zdravilih uporablja že mnogo let, vključno pri zdravljenju levkemije.
Other information about Trisenox 
Druge informacije o zdravilu Trisenox
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Trisenox have been included in the summary of product characteristics and the package leaflet. 
Priporočila in varnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Trisenox upoštevati zdravstveni delavci in bolniki, so vključeni v povzetek glavnih značilnosti zdravila in navodilo za njegovo uporabo.
During the consolidation phase, Trisenox is given once a day for five days, followed by a two-day break, repeated for four or five weeks. 
Med utrditveno stopnjo se zdravilo daje enkrat na dan pet dni zapored, čemur sledi dvodnevna prekinitev, vse skupaj pa je treba ponavljati štiri ali pet tednov.
Patients with APL are normally treated with retinoids (substances derived from vitamin A). 
Bolniki z akutno promielocitno levkemijo se navadno zdravijo z retinoidi (snovmi, pridobljenimi iz vitamina A).
The translocation affects the way the white blood cells grow, and as a result they lack the ability to use retinoic acid (vitamin A). 
Translokacija prizadene rast belih krvnih celic, zaradi česar posledično ne morejo izrabljati retinojske kisline (vitamina A).
Trisenox is used in: 
Zdravilo Trisenox se uporablja pri:
Trisenox was not compared with any other medicine in either study. 
V nobeni študiji zdravila Trisenox niso primerjali z drugimi zdravili.
Trisenox is used to treat adults (aged 18 years or over) with acute promyelocytic leukaemia (APL), a rare form of leukaemia (cancer of the white blood cells) caused by a genetic ‘translocation' (when there is a swap of genes between two chromosomes). 
Zdravilo Trisenox se uporablja za zdravljenje odraslih (starejših od 18 let) z akutno promielocitno levkemijo (APL), tj. redko obliko levkemije (rakom belih krvnih celic)., ki jo povzroča genetska „translokacija“ (zamenjava genov med dvema kromosomoma).
For the full list of all side effects and restrictions with Trisenox, see the package leaflet. 
Za celoten seznam neželenih učinkov in omejitev pri uporabi zdravila Trisenox glejte navodilo za uporabo.
It is not intended to provide practical advice on how to use Trisenox. 
Povzetek ni namenjen zagotavljanju praktičnih nasvetov o njegovi uporabi.
For more information about treatment with Trisenox, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Za več informacij o zdravljenju z zdravilom Trisenox preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
What are the risks associated with Trisenox? 
Kakšna tveganja so povezana z zdravilom Trisenox?
Why is Trisenox approved? 
Zakaj je bilo zdravilo Trisenox odobreno?
Trisenox can only be obtained with a prescription and treatment should be supervised by a doctor who has experience in the management of patients with acute leukaemias. 
Predpisovanje in izdaja zdravila Trisenox je le na recept, zdravljenje z njim pa mora nadzorovati zdravnik, ki ima izkušnje z zdravljenjem bolnikov z akutnimi oblikami levkemije.
The recommended dose of Trisenox depends on the body weight of the patient. 
Priporočeni odmerek zdravila Trisenox je odvisen od telesne mase bolnika.
What benefits of Trisenox have been shown in studies? 
Kakšne koristi je zdravilo Trisenox izkazalo v študijah?
Trisenox has also been investigated in two studies involving a total of 52 patients with APL who had been previously treated with an anthracycline and a retinoid. 
Zdravilo Trisenox je bilo raziskano tudi v dveh študijah, v katerih je skupaj sodelovalo 52 bolnikov z akutno promielocitno levkemijo, ki so bili predhodno zdravljeni z antraciklinom in retinoidom.
What is Trisenox and what is it used for? 
Kaj je zdravilo Trisenox in za kaj se uporablja?
• Patients with newly diagnosed low or intermediate risk APL where it is used together with the medicine all-trans-retinoic acid (ATRA). 
• bolnikih z novo diagnosticirano nizko ali srednjo stopnjo tveganja za nastanek akutne promielocitne levkemije, kadar se zdravilo jemlje skupaj z zdravilom, ki vsebuje vse-transretinojsko kislino (ATRA);
For practical information about using Trisenox, patients should read the package leaflet or contact their doctor or pharmacist. 
Za praktične informacije o uporabi zdravila Trisenox naj bolniki preberejo navodilo za uporabo ali se posvetujejo z zdravnikom ali farmacevtom.
Trisenox arsenic trioxide 
Trisenox arzenov trioksid
The number of times these cycles are repeated depends on whether patients have received previous treatment or not. 
Število ponovljenih ciklov je odvisno od tega, ali so bili bolniki predhodno že zdravljeni ali ne. Za več informacij glejte navodilo za uporabo.
Trisenox contains the active substance arsenic trioxide. 
Zdravilo Trisenox vsebuje zdravilno učinkovino arzenov trioksid.
How does Trisenox work? 
Kako zdravilo Trisenox deluje?
How is Trisenox used? 
Kako se zdravilo Trisenox uporablja?
Trisenox has been investigated in 159 newly diagnosed patients who had not yet received any treatment for APL. Trisenox was compared with an anthracycline (a type of cancer medicine), both taken in combination with ATRA, and the measure of effectiveness was the number of patients who did not experience any event (such as worsening of their disease or death) 2 years after diagnosis. 
Glavno merilo učinkovitosti je bilo število bolnikov, pri katerih se dve leti po postavljeni diagnozi ni pojavil noben dogodek (npr. poslabšanje bolezni ali smrt).
At the request of the CHMP, an ad-hoc expert advisory group meeting was convened in February 2013. 
Na zahtevo odbora CHMP je bil februarja 2013 sklican sestanek ad hoc svetovalne strokovne skupine.
However these imbalances involved small numbers of events. 
Vendar pa razlike temeljijo na majhnem številu dogodkov.
Overall summary of the scientific evaluation of cilostazol containing medicinal products (see Annex I) 
Splošni povzetek znanstvenega vrednotenja zdravil, ki vsebujejo cilostazol (glejte Prilogo I)
Results for secondary efficacy endpoints were consistent with the results for ACD. 
Rezultati za sekundarne opazovane dogodke učinkovitosti so bili skladni z rezultati za ACD.
• The Committee considered the procedure under Article 31 of Directive 2001/83/EC on cilostazolcontaining medicinal products; 
• Odbor je obravnaval napotitev v skladu s členom 31 Direktive 2001/83/ES za zdravila, ki vsebujejo cilostazol;
The protocol of the studies was agreed by the CHMP. 
Protokol študij je odobril CHMP.
It was recognised that less adverse events than expected had been reported. 
Strinjali so se, da je bilo poročil o neželenih dogodkih manj, kot so pričakovali.
The CASTLE study included patients who were treated up to 3 years. 
V študiji CASTLE so bolniki zdravilo prejemali do 3 leta.
• The Committee reviewed all the data provided by the MAHs in writing and in the oral explanation and the outcome of the ad-hoc expert advisory group meeting; 
• Odbor je preučil vse podatke, ki so jih imetniki dovoljenj za promet z zdravili podali v obliki pisne dokumentacije in ustnih obrazložitev, ter ugotovitve s sestanka ad hoc strokovne svetovalne skupine;
The CHMP also agreed to the introduction of measures to ensure health care professionals are informed on the conditions of use of the product. 
CHMP je odobril uvedbo ukrepov, s katerimi bi zagotovili seznanjenost zdravstvenih delavcev s pogoji uporabe zdravila.
The primary objective of the CASTLE trial was to assess the long-term effect of cilostazol on all-cause mortality. 
Glavni cilj študije CASTLE je bil oceniti dolgoročni učinek cilostazola na smrtnost iz katerega koli razloga.
This Article 31 referral was initiated by Spain following review of safety reports received in association with cilostazol during the first 18 months of marketing in Spain (cilostazol was licenced in Spain in 2008). 
Napotitev v skladu s členom 31 je sprožila Španija, potem ko je pregledala poročila o varnosti, povezana z uporabo cilostazola v prvih 18 mesecih trženja zdravila v Španiji (cilostazol je bil v Španiji odobren leta 2008).
The CHMP also concluded that the risk of bleeding was higher in patients treated concomitantly with two or more additional antiplatelet or anticoagulants agents. 
CHMP je zaključil tudi, da je bilo tveganje za krvavitve večje pri bolnikih, ki so bili sočasno zdravljeni z dvema ali več drugimi antiagregacijskimi ali antikoagulacijskimi zdravili.
In order to measure the effectiveness of the above measures, the CHMP has agreed on two drug utilisation studies (DUS). 
Da bi ocenili učinkovitost omenjenih ukrepov, je CHMP odobril dve študiji uporabe zdravila.
Suitability of treatment with cilostazol should be carefully considered, alongside other treatment options such revascularisation. 
Primernost zdravljenja s cilostazolom je treba skrbno preučiti skupaj z drugimi možnostmi zdravljenja, kot je na primer revaskularizacija.
The need to review the patient's response to treatment at 3 months and to continue treatment only if positive was agreed by all. 
Vsi so se strinjali, da je treba po treh mesecih preučiti odziv bolnika in nadaljevati zdravljenje samo, če je ta pozitiven.
Therefore the CHMP recommended the variation to the terms of the Marketing Authorisations for the cilostazol-containing medicinal products referred to in Annex I, in accordance to the amendments to the Summary of Product Characteristics, Labelling and Package Leaflet set out in Annex III and subject to the conditions set out in Annex IV. 
Zato je CHMP priporočil spremembo pogojev dovoljenj za promet z zdravili, ki vsebujejo cilostazol, navedenimi v Prilogi I, skladno s spremembami povzetka glavnih značilnosti zdravila, označevanja in navodila za uporabo, opredeljenimi v Prilogi III, ter s pogoji, navedenimi v Prilogi IV.
To ensure that health care professionals are informed of the correct indication for use of the product, the MAH has introduced the following measures: proactive communication to physicians on the Otsuka Europe website, re-training of the Medical Information teams and Sales Force teams in the countries where cilostazol is marketed. 
Za zagotovitev seznanjenosti zdravstvenih delavcev z ustrezno indikacijo za uporabo zdravila je imetnik dovoljenja za promet z zdravilom predlagal naslednje ukrepe: aktivno obveščanje zdravnikov prek spletne strani družbe Otsuka Europe ter ponovno usposabljanje ekip za posredovanje zdravstvenih informacij in prodajnih ekip v državah, v katerih se trži cilostazol.
Spain therefore referred cilostazol to the CHMP/EMA, requesting that it gives its opinion under Article 31 of Directive 2001/83/EC, on whether the marketing authorisations for medicinal products containing cilostazol should be maintained, varied, suspended or withdrawn. 
Zato je Španija za cilostazol sprožila napotitev v skladu s členom 31 Direktive 2001/83/ES in zahtevala, da CHMP/EMA poda mnenje o tem, ali je treba dovoljenja za promet z zdravili, ki vsebujejo cilostazol, ohraniti, spremeniti, začasno umakniti ali preklicati.
The efficacy of cilostazol has been evaluated in 14 clinical trials which enrolled more than 4000 intermittent claudication (IC) patients. 
Klinično učinkovitost cilostazola so ocenjevali v 14 kliničnih preskušanjih, v katera je bilo vključenih več kot 4 000 bolnikov z intermitentno klavdikacijo (IK).
This leads to inhibition of platelet activation and aggregation and prevents the release of prothrombotic inflammatory and vasoactive substances. 
Tako zavira aktiviranje in agregacijo trombocitov ter preprečuje sproščanje protrombotičnih vnetnih in vazoaktivnih snovi.
The group considered that it was feasible to exclude high cardiovascular risk patients in practice, and that this would also limit the risk of drug interaction with antiplatelet agents (as most patients in these groups would receive dual antiplatelet therapy). 
Skupina je menila, da je mogoče v praksi izključiti bolnike z visokim kardiovaskularnim tveganjem, s čimer bi omejili tudi tveganje za medsebojno delovanje z antiagregacijskimi zdravili (ker večina bolnikov iz te skupine prejema dvotirno antiagregacijsko zdravljenje).
In total 3,122 patients were randomised and received at least one dose of investigational product in the 9 efficacy trials. 
V devetih študijah učinkovitosti so skupno randomizirali 3 122 bolnikov, ki so prejeli vsaj en odmerek preiskovanega zdravila.